Preface | |
List of Contributors | |
Structure-Function Studies of the Voltage-Dependent Calcium Channels | p. 1 |
Regulation of Calcium Channels by Protein Phosphorylation | p. 9 |
Interactions of Lacidipine and Other Calcium Channel Drugs with Biological Membranes: A Structural Model for Receptor/Drug Binding Utilizing the Membrane Bilayer | p. 15 |
Regulation of Calcium Channels in Vascular Smooth Muscle | p. 25 |
Calcium and the Production of Endothelium-Derived Vasoactive Factors | p. 31 |
Postnatal Development of Calcium Channels in Cardiac Muscle | p. 37 |
The Hemodynamic Effects of Calcium Antagonists under Pathological Conditions | p. 43 |
Calcium, Ischemia, and the Calcium Antagonists | p. 49 |
Multiple Organ Protection through Endothelial Cell Stabilization: A Mechanism of Action of Calcium Antagonists? | p. 59 |
New Insight into the Vascular Properties of Lacidipine | p. 65 |
Effect of Felodipine on Left Ventricular Performance in Conscious Dogs: Assessment by Left Ventricular Pressure-Volume Analysis | p. 71 |
Lacidipine in the Treatment of Hypertension: Clinical Data | p. 77 |
Insights in the Cardioprotective Mechanism of the New Drug R56865 | p. 87 |
Do the Differences between Calcium Antagonists Matter when Treating Hypertension? | p. 93 |
Effects of Lacidipine on Ischemic and Reperfused Myocardium | p. 99 |
Atherogenic Activity Caused by Excess Membrane Cholesterol in Arterial Smooth Muscle: Role of Calcium Channels | p. 107 |
Understanding the Initiating Factors in Atherosclerosis: Implications for Intervention | p. 117 |
Calcium Antagonists and Lipid-Lowering Agents in the Protection of the Arterial Wall | p. 125 |
Calcium Channel Blockers as Agents for the Treatment of Atherosclerosis | p. 133 |
Anti-Arteriosclerotic Effects of Calcium Antagonists: Do Calcium Antagonists Inhibit Cholesterol Accumulation in Coronary Arteries of Cholesterol-Fed Rabbits? | p. 139 |
Cholesterol Enrichment during Dietary Atherosclerosis Alters Smooth Muscle Plasma Membrane Width and Structure: Evidence for Reversal by the 1,4-Dihydropyridine Amlodipine | p. 149 |
Lacidipine and Atherosclerosis | p. 157 |
Potentiation of the Antiplatelet Effect of Aspirin by the Calcium Channel Antagonist Amlodipine | p. 165 |
The Effects of Lacidipine on Insulin Sensitivity | p. 173 |
Calcium Antagonists, Hypertension, and Atherosclerosis | p. 179 |
Expression, Localization, and Function of Calcium Channels in NGF-Treated PC12 Cells | p. 183 |
Receptor-Mediated Inhibition of Calcium Currents and Synaptic Transmission in Cultured Hippocampal Pyramidal Neurons | p. 189 |
Calcium Stores and Calcium Channels of Cerebellum Purkinje Cells | p. 195 |
Calcium Channel Signaling in Astrocytes | p. 205 |
Studies on Synaptosomes: New Insights on Calcium Antagonists | p. 215 |
The Regulation of Neuronal Calcium Channels | p. 221 |
Effect of Aging on Brain Voltage-Dependent Calcium Channels | p. 231 |
Calcium Overload Blockade in Neurons and Cardiomyocytes | p. 241 |
Effect of Nicardipine on Antioxidant Enzymatic Activities and LTC[subscript 4] Release in Experimental SAH | p. 249 |
Treatment of Acute Ischemic Stroke with Calcium Antagonists | p. 257 |
Pharmacological Approach to Acute Ischemic Stroke | p. 265 |
Calcium Antagonist and Subarachnoid Hemorrhage | p. 271 |
Pharmacological Basis for Use of Calcium Antagonists in Dementia | p. 279 |
Calcium Channels in Intestinal Smooth Muscle | p. 285 |
Pharmacological Aspects of Calcium Channels in Nonvascular Smooth Muscle | p. 291 |
Pharmacology of Calcium Antagonists Active on Gastrointestinal Calcium Channels | p. 299 |
Role of Calcium Channels in Pharmacological Modulation of Gastrointestinal Motility | p. 315 |
A New Class of Calcium Antagonist Selective for the GI Tract | p. 325 |
Therapeutic Application of Calcium Antagonists in Gastroenterology | p. 337 |
Calcium Antagonists and the Kidney: Implications for Renal Protection | p. 349 |
Calcium Antagonists Improve the Outcome after Renal Transplantation | p. 355 |
Reversal of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells by Calcium Channel Antagonists | p. 363 |
Reversal of Multiple Drug Resistance (MDR) in Malaria by Reverse Isomers of Calcium Channel Blockers and its Possible Application to Cancer and MDR Parasitic Diseases | p. 369 |
Index | p. 377 |
Table of Contents provided by Blackwell. All Rights Reserved. |